Psychiatry near Lyndhurst, NJ

Biography: J John Mann MD, is The Paul Janssen Professor of Translational Neuroscience (in Psychiatry and in Radiology) and a former Vice Chair for Research in the Department of Psychiatry at Columbia University. He is Director of Research and Director of Molecular Imaging and the Neuropathology Division at the New York State Psychiatric Institute. Dr. Mann is trained in Psychiatry and Internal Medicine and has a Doctorate in Neurochemistry. His research employs functional brain imaging, neurochemistry and molecular genetics to probe the causes of depression and suicide. Dr. Mann is the Director of the NIMH Conte Center for the Neuroscience of Mental Disorders, and Past President of the International Academy of Suicide Research. Dr. Mann has published 458 papers and edited 10 books on the subjects of the biology and treatment of mood disorders, suicidal behavior and other psychiatric disorders. In private practice he specializes in the treatment of mood disorders.

Biography: Dr. Attia received her A.B. from Princeton University in 1982 and her MD from Columbia University College of Physicians & Surgeons in 1986. Formerly the director of the inpatient eating disorders program at The New York State Psychiatric Institute, Dr. Attia has more recently focused on research involving the psychobiology and treatment of anorexia nervosa. Since 1999, she has received uninterrupted funding for her research from the National Institute of Mental Health (NIMH). Dr. Attia has received a Young Investigator Award from The National Alliance for Research in Schizophrenia and Depression (NARSAD), a Pfizer/Society for Women's Health Research Faculty Development Award in Women's Health, and a Career Development Award from NIMH. Dr. Attia is a member of the eating disorders work-group for DSM-5. She is also a member of The Eating Disorders Research Society and has been elected Fellow of the Academy for Eating Disorders.

Biography: Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University. For over twenty years, she served as the Director of the Addiction Psychiatry Fellowship Program at New York-Presbyterian Hospital and for the past sixteen years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship which has been continuously funded since 1994. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic. Subsequently, she graduated from a 2-year combined clinical and research fellowship at the University of Maryland and the Addiction Research Center, the intramural branch of the National Institute on Drug Abuse (NIDA). Currently, she serves as the Medical Director of the Providers' Clinical Support System (PCSS), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director of a SAMHSA-supported State Targeted Response technical assistance grant (the Opioid Response Network) to address the national opioid epidemic. Dr. Levin, working with other senior faculty, inaugurated the university-wide Center for Healing of Opioid and Other Substance Use Disorders: Enhancing Intervention Development and Implementation (CHOSEN) in 2020 and serves as one of the senior Directors. Moreover, she is the principal investigator of several federal grants, including a K24 Mid-Career Investigator Award as well as a Co-Investigator on numerous other grants. Her current research interests include pharmacologic and psychotherapeutic treatment interventions for opioid, cocaine and marijuana use disorders, and treatment approaches for adults with substance use disorders and attention-deficit hyperactivity disorder along with other psychiatric illnesses. Dr. Levin has over two-hundred and fifty articles and book chapters on a wide range of topics including treatments of substance use disorders, assessment, and treatment of co-occurring psychiatric illnesses and vulnerabilities associated with substance use disorders. She has served on several advisory panels and ad-hoc federal grant review groups and was a member of the NIDA Initial Review Group: Training and Career Development Subcommittee for eight years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She is currently on the Board of Directors for the American Academy of Addiction Psychiatry (AAAP), the College on Drug Dependence (CPDD), and the American Society of ADHD and Related Disorders (APSARD). She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry, and past Chair of the APA Council on Addiction Psychiatry.

Biography: Laurel Mayer, M.D. is Associate Professor of Clinical Psychiatry at the Columbia University College of Physicians and Surgeons. She received a BA at Yale University and her MD degree at the Albert Einstein College of Medicine. Dr. Mayer's research interest currently focuses on using sophisticated eating behavior paradigms to evaluate eating behavior across the eating and weight disordered spectrum. Building on successful studies of eating behavior in anorexia nervosa, Dr. Mayer is currently exploring (1) the potential influence of the FTO gene on eating behavior and fronto-striatal brain circuits in healthy, normal weight kids, in order to potentially identify risk factors for later weight gain. (2) the potential biological correlates of weight suppression (the difference between one's lifetime and current weight) in women with bulimia nervosa in order to test the hypothesis that higher levels of weight suppression and currently being on a diet to lose weight, will be independently associated with lower resting metabolic rate and lower levels of metabolic (e.g. thyroid), reproductive (e.g., estrogen) and appetitive (e.g., leptin) hormone levels among women with bulimia nervosa. (3) the utility of short-term residential laboratory-based measures in predicting the longer-term effects of pharmacologic agents in promoting weight loss. (4) measuring the influence of dietary macronutrients distributions (e.g. low carb compared to standard American) on intake and energy expenditure and (5) evaluating the weight gain and related metabolic side effects of second-generation antipsychotics.

Biography: Lisa Dixon, MD, MPH, is a Professor of Psychiatry at the Columbia University Medical Center and the director of the Division of Behavioral Health Services and Policy Research within the Department of Psychiatry. She also directs the Center for Practice Innovations (CPI) at the New York State Psychiatric Institute. Dr. Dixon is an internationally recognized health services researcher with over 25 years of continuous funding from the National Institute of Mental Health and the VA. As CPI director, she oversees activities for the New York State Office of Mental Health in implementing evidenced based practices for persons diagnosed with serious mental illness. She is leading the innovative program, OnTrackNY, a statewide initiative designed to improve outcomes and reduce disability for the population of individuals experiencing their first episode of psychosis. Dr. Dixon's grants have focused on improving the quality of care for individuals with serious mental disorders with a particular emphasis on services that include families, reducing the negative impact of co-occurring addictions and medical problems, and improving treatment engagement and adherence. Dr. Dixon's work has joined individuals engaged in self-help, outpatient psychiatric care, as well as clinicians and policy makers in collaborative research endeavors. Dr. Dixon assumed the role of editor in chief of the journal, Psychiatric Services in January, 2017. She has published more than 350 articles in peer-reviewed journals and has received numerous awards including the 2009 American Psychiatric Association Health Services Senior Scholar Award and the Wayne Fenton Award for Exceptional Clinical Care. In 2014, the National Alliance on Mental Illness (NAMI) Metro NYC recognized her with the Adele Anshien Volunteer of the Year Award, and NAMI national recognized her with its annual Scientific Research Award. In 2022, the American College of Psychiatrists recognized her work with the Stanley Dean Award.

Biography: T. Scott Stroup, MD, MPH, is a Professor of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons. Dr. Stroup's research focuses on the effectiveness of interventions and services for people diagnosed with schizophrenia and related illnesses. He was co-principal investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and director of the Schizophrenia Trials Network. He conducts research examining treatment strategies for schizophrenia. He is principal investigator of the OPAL Center, a National Institute of Mental Health supported center that focuses on examining interventions for schizophrenia that have real-world applications. His other interests include global mental health and the dissemination of evidence-based practices.